OncoMatch

OncoMatch/Clinical Trials/NCT07218809

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Is NCT07218809 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for epithelial ovarian cancer.

Phase 3RecruitingAstraZenecaNCT07218809Data as of May 2026

Treatment: AZD5335 · Mirvetuximab Soravtansine (MIRV) · Paclitaxel · Pegylated liposomal Doxorubicin (PLD) · Topotecan — The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα levels.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Biomarker criteria

Allowed: BRCA1 mutation

Participants with documented BRCA mutation (germline and/or somatic) must have received prior PARPi if the participant is eligible per approved label and standard-of-care institutional guidelines, except in cases of documented contraindication, precaution or intolerance.

Allowed: BRCA2 mutation

Participants with documented BRCA mutation (germline and/or somatic) must have received prior PARPi if the participant is eligible per approved label and standard-of-care institutional guidelines, except in cases of documented contraindication, precaution or intolerance.

Prior therapy

Max 3 prior lines
Min 1 prior line

Must have received: platinum-based chemotherapy

Participants must have platinum-resistant disease

Cannot have received: FRα-targeted therapy (mirvetuximab soravtansine)

Prior treatment with any FRα-targeted therapy, including MIRV

Cannot have received: TOP1i antibody-drug conjugate

Prior treatment with any TOP1i ADC

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Research Site · Fort Lauderdale, Florida
  • Research Site · Jupiter, Florida
  • Research Site · Evanston, Illinois
  • Research Site · Peoria, Illinois
  • Research Site · Urbana, Illinois

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify